EXTRANODAL NK/T-CELL LYMPHOMA
Clinical trials for EXTRANODAL NK/T-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new EXTRANODAL NK/T-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for EXTRANODAL NK/T-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at Hard-to-Treat blood cancers
Disease control OngoingThis early-stage trial tests a new treatment called WU-CART-007 for people with certain blood cancers (like acute myeloid leukemia and T-cell lymphoma) that have not responded to standard therapy. The treatment uses donor immune cells that are specially modified to target and kil…
Matched conditions: EXTRANODAL NK/T-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 08, 2026 12:02 UTC
-
New hope for rare lymphoma: experimental drug IMC-001 tested in 23 patients
Disease control OngoingThis study tests an experimental drug called IMC-001 in 23 adults with a rare lymphoma (extranodal NK/T-cell lymphoma) that has returned or not improved after prior therapy. The main goal is to see if the drug can shrink tumors. Participants receive the drug and are monitored for…
Matched conditions: EXTRANODAL NK/T-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: ImmuneOncia Therapeutics Inc. • Aim: Disease control
Last updated May 04, 2026 16:19 UTC